Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, Eli Lilly Over the Last 8 Quarters

A Comparative Analysis of Net Income Margins in Leading Pharmaceutical Companies

In the ever-evolving pharmaceutical industry, financial health is a key indicator of a company's success. Over the past two years, we have observed the net income margins of four major players: GlaxoSmithKline (GSK), AstraZeneca (AZN), Takeda (TAK), and Eli Lilly (LLY). This analysis provides a snapshot of their financial performance over the last eight quarters.

Key Insights

• Eli Lilly (LLY) has shown remarkable performance with an average net income margin of approximately 21%, peaking at 26% in early 2024. This indicates a strong profitability trend.
• GlaxoSmithKline (GSK) and AstraZeneca (AZN) have maintained steady margins around 15% and 14% respectively, showcasing consistent financial health.
• Takeda (TAK), however, has lagged behind with an average net income margin of just 6%, reflecting potential challenges in maintaining profitability.

Trends Over Time

The data reveals that Eli Lilly consistently outperformed its peers, while Takeda struggled to keep pace. Notably, there were missing data points for some quarters, which could indicate reporting delays or other anomalies.

This comparative analysis underscores the importance of financial metrics in evaluating the performance and stability of pharmaceutical giants. Stay tuned for more insights as we continue to monitor these industry leaders.